Sanofi - Aventis Groupe: Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and only medicine to demonstrate positive Phase